Evidence map›Paper›PMID 41102183›Full record

ArticleCell death & disease2025

The E3 ubiquitin ligase TRIM56 promotes aggregation and activation of Src protein through Lys63-linked polyubiquitination in hepatocellular carcinoma.

Lihui Zhu, Xiuling Cui, Hongwei Xu, Min Yang, Lihui Han

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lihui Zhu *Department of Immunology, Shandong Provincial Key Laboratory of Infection & Immunology, Shandong University School of Basic Medical Sciences, Jinan, Shandong, China.
Xiuling Cui *Department of Immunology, Shandong Provincial Key Laboratory of Infection & Immunology, Shandong University School of Basic Medical Sciences, Jinan, Shandong, China.
Hongwei XuDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Min YangDepartment of Immunology, Shandong Provincial Key Laboratory of Infection & Immunology, Shandong University School of Basic Medical Sciences, Jinan, Shandong, China.
Lihui HanDepartment of Immunology, Shandong Provincial Key Laboratory of Infection & Immunology, Shandong University School of Basic Medical Sciences, Jinan, Shandong, China. hanlihui@sdu.edu.cn.ORCID http://orcid.org/0000-0003-1030-2232

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82103075National Natural Science Foundation of China (National Science Foundation of China) 82171748National Natural Science Foundation of China (National Science Foundation of China) 82472725Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation) ZR2021QH185Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation) ZR2023LZL010
6 · The paper itself

Abstract

Elevated activity of proto-oncogene tyrosine kinase Src is associated with tumorigenesis and progression of hepatocellular carcinoma (HCC). It is well recognized that activation of Src is mainly driven by its intermolecular autophosphorylation. However, the precise mechanism involved in the activation of Src remains to be fully understood. Here we identified tripartite motif-containing protein (TRIM) 56, a member of E3 ubiquitin ligase family, as a novel regulator of Src activation. The data revealed that TRIM56 directly interacted with Src and catalyzed the polyubiquitination and subsequent aggregation of Src, resulting in Src activation and HCC progression. Mechanistically, TRIM56 interacted with the SH3 domain of Src protein via its B-box1 domain and catalyzed the Lys63-linked polyubiquitination of Src at the Lys184 residue, leading to the aggregation and activation of Src. Altogether, here we demonstrated that TRIM56 acted as a tumor promoter in HCC and it exerted a novel regulatory effect on Src activation. Thus, this study suggested a promising therapeutic strategy for HCC patients by targeting TRIM56.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsLysinesrc-Family KinasesTripartite Motif ProteinsUbiquitin-Protein LigasesAnimalsCell Line, TumorHEK293 CellsHumansMiceMice, NudeProtein BindingProto-Oncogene MasUbiquitinationLysineMAS1 protein, humanProto-Oncogene Massrc-Family KinasesTripartite Motif ProteinsUbiquitin-Protein Ligases

Identifiers

PMID41102183
PMCPMC12533068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.